Trifluoromethylaminoindane
Trifluoromethylaminoindane[edit | edit source]
Trifluoromethylaminoindane (TFMAI) is a chemical compound that belongs to the class of substituted amphetamines. It is a derivative of aminoindane and is characterized by the presence of a trifluoromethyl group attached to the aminoindane structure.
Chemical Properties[edit | edit source]
Trifluoromethylaminoindane is known for its unique chemical properties, which are influenced by the trifluoromethyl group. This group is known to enhance the lipophilicity of the compound, potentially affecting its pharmacokinetic properties. The presence of the trifluoromethyl group can also influence the compound's electron-withdrawing characteristics, which may impact its interaction with biological targets.
Synthesis[edit | edit source]
The synthesis of trifluoromethylaminoindane typically involves the introduction of the trifluoromethyl group into the aminoindane structure. This can be achieved through various chemical reactions, including nucleophilic substitution or electrophilic fluorination. The specific methods used can vary depending on the desired yield and purity of the final product.
Pharmacology[edit | edit source]
Trifluoromethylaminoindane is of interest in the field of pharmacology due to its potential effects on the central nervous system. As a derivative of aminoindane, it may interact with monoamine neurotransmitter systems, although specific studies on its pharmacological profile are limited. Research into its effects and potential therapeutic applications is ongoing.
Safety and Toxicology[edit | edit source]
The safety and toxicological profile of trifluoromethylaminoindane is not well-documented. As with many novel compounds, caution is advised in its handling and use. Potential risks may include neurotoxicity, cardiotoxicity, and other adverse effects associated with similar compounds.
Related Compounds[edit | edit source]
Trifluoromethylaminoindane is related to other aminoindane derivatives, such as 2-Aminoindane and 5,6-Methylenedioxy-2-aminoindane (MDAI). These compounds share a similar core structure but differ in their substituents, which can significantly alter their pharmacological properties.
Related Pages[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD